[Controlled, clinical trial of isoprinosine administration to HIV-infected patients. Results of a Danish/Swedish multicenter study. The Scandinavian Isoprinosine Study Group].

Abstract

The safety and efficacy of isoprinosine in HIV-infected individuals were assessed in a multicentre, randomized, double-blind, 24-week study phase, followed by an optional 24-week open treatment phase. The results of the double-blind phase have been reported separately. Of 866 HIV-seropositive individuals randomized, 832 were eligible for efficacy analysis. On completion of the double-blind phase, 596 patients started open treatment. All patients were evaluated with regard to progression to AIDS. Within 48 weeks, 10/412 patients (2.4%) assigned isoprinosine and 27/420 (6.4%) assigned placebo progressed to AIDS (p = 0.005; odds ratio: 2.8, 95% CI: 1.3-6.2). Intention-to-treat analysis showed identical results. No severe adverse reactions or toxicities were observed. We conclude that HIV-infected individuals without AIDS may be safely and effectively treated with isoprinosine.

• Authors: S Thorsen, C Pedersen, E Sandström, C S Petersen, G Norkrans, J Gerstoft, A Karlsson, K C Christensen, C Håkansson, P O Pehrson
• Journal: Ugeskrift for laeger (Ugeskr Laeger) Vol. 156 Issue 22 Pg. 3314-8 (May 30 1994) ISSN: 0041-5782 [Print] Denmark
• Vernacular Title: Kontrolleret, klinisk afprøvning af isoprinosin til HIV-smittede. Resultater af en dansk/svensk multicenterundersøgelse. The Scandinavian Isoprinosine Study Group.
• PMID: 7520643 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Inosine Pranobex

Topics

• Acquired Immunodeficiency Syndrome (etiology, prevention & control)
• Denmark
• Double-Blind Method
• HIV Infections (drug therapy)
• Humans
• Inosine Pranobex (administration & dosage)
• Sweden